Next Article in Journal
Inter- and Intraprovincial Inequities in Public Coverage of Cancer Drug Programs across Canada: A Plea for the Establishment of a Pan-Canadian Pharmacare Program
Previous Article in Journal
Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

1
Department of Hematology and Medical Oncology, University of Manitoba, and CancerCare Manitoba, Winnipeg, MB, Canada
2
Department of Medicine, Division of Hematology, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, QC, Canada
3
impactMedicom Inc., Toronto, ON, Canada
4
The Ottawa Hospital, Ottawa, ON, Canada
5
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and University of Toronto, Toronto, ON, Canada
6
University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada
7
Hoffmann–La Roche, Mississauga, ON, Canada
8
Division of Medical Oncology, University of British Columbia, and BC Cancer, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(4), 253-265; https://doi.org/10.3747/co.26.5421
Received: 1 May 2019 / Revised: 4 June 2019 / Accepted: 12 July 2019 / Published: 1 August 2019
Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In eligible patients, salvage therapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard of care. However, many patients are transplant-ineligible, and more than half of those undergoing asct will subsequently relapse. For those patients, outcomes are dismal, and novel treatment approaches are a critical unmet need. In this paper, we present available data about emerging treatment approaches in the latter setting and provide a perspective about the potential use of those approaches in Canada.
Keywords: Diffuse large B cell lymphoma; DLBCL; non-Hodgkin lymphoma; novel therapies Diffuse large B cell lymphoma; DLBCL; non-Hodgkin lymphoma; novel therapies
MDPI and ACS Style

Skrabek, P.; Assouline, S.; Christofides, A.; MacDonald, D.; Prica, A.; Sangha, R.; Matthews, B.A.; Sehn, L.H. Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma. Curr. Oncol. 2019, 26, 253-265. https://doi.org/10.3747/co.26.5421

AMA Style

Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, Matthews BA, Sehn LH. Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma. Current Oncology. 2019; 26(4):253-265. https://doi.org/10.3747/co.26.5421

Chicago/Turabian Style

Skrabek, P., S. Assouline, A. Christofides, D. MacDonald, A. Prica, R. Sangha, B.A. Matthews, and L.H. Sehn 2019. "Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma" Current Oncology 26, no. 4: 253-265. https://doi.org/10.3747/co.26.5421

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop